The Food and Drug Administration on Tuesday approved Shire's attention deficit hyperactivity disorder treatment, Mydayis.
Here are three things to know.
- Mydayis is intended to treat ADHD symptoms in patients thirteen years or older.
- The once-daily drug features the same active ingredients as Shire's popular ADHD drug Adderall, but is formulated to last up to 16 hours, according to Reuters.
- Shire plans to launch Mydayis in the third quarter of this year.
More articles on supply chain:
Global drug sales forecast falls for 1st time in decade
Stryker to acquire imaging technology company for $701M
SCOTUS decision reduces drugmakers' product liability